Compare GERN & OCSL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GERN | OCSL |
|---|---|---|
| Founded | 1990 | 2007 |
| Country | United States | United States |
| Employees | 229 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.0B |
| IPO Year | N/A | 2007 |
| Metric | GERN | OCSL |
|---|---|---|
| Price | $1.55 | $11.15 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 3 | 5 |
| Target Price | $2.17 | ★ $13.10 |
| AVG Volume (30 Days) | ★ 17.1M | 771.9K |
| Earning Date | 05-06-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 14.12% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.06 |
| Revenue | N/A | N/A |
| Revenue This Year | $26.91 | N/A |
| Revenue Next Year | $43.75 | $0.31 |
| P/E Ratio | ★ N/A | $188.92 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.04 | $10.63 |
| 52 Week High | $2.01 | $15.69 |
| Indicator | GERN | OCSL |
|---|---|---|
| Relative Strength Index (RSI) | 48.18 | 42.80 |
| Support Level | $1.24 | $11.09 |
| Resistance Level | $1.70 | $13.89 |
| Average True Range (ATR) | 0.10 | 0.25 |
| MACD | -0.01 | 0.04 |
| Stochastic Oscillator | 37.50 | 61.61 |
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.
Oaktree Specialty Lending Corp is a specialty finance company. The company provides lending services and invests in small and mid-sized companies. The company's investment objective is to maximize its portfolio's total return by generating current income from debt investments, and to a lesser extent, capital appreciation from equity investments. The company provides customized, one-stop credit solutions to companies with limited access to public or syndicated capital markets. The company operates as a single reportable segment and derives revenues from investing in originated loans and other securities, including broadly syndicated loans, of U.S. private companies and manages the business on a consolidated basis.